347 related articles for article (PubMed ID: 29202855)
1. Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
Morello S; Capone M; Sorrentino C; Giannarelli D; Madonna G; Mallardo D; Grimaldi AM; Pinto A; Ascierto PA
J Transl Med; 2017 Dec; 15(1):244. PubMed ID: 29202855
[TBL] [Abstract][Full Text] [Related]
2. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
4. NMR-Based Assay for the
He Y; Zhao Y; Nelson DM; Klippel A; Reily MD
Anal Chem; 2020 Nov; 92(21):14501-14508. PubMed ID: 32985862
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD73 in Critically Ill Septic Patients - Data from the Prospective FINNAKI Study.
Vaara ST; Hollmén M; Korhonen AM; Maksimow M; Ala-Kokko T; Salmi M; Jalkanen S; Pettilä V;
PLoS One; 2016; 11(10):e0164420. PubMed ID: 27732656
[TBL] [Abstract][Full Text] [Related]
7. Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.
Turiello R; Capone M; Morretta E; Monti MC; Madonna G; Azzaro R; Del Gaudio P; Simeone E; Sorrentino A; Ascierto PA; Morello S
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35273100
[TBL] [Abstract][Full Text] [Related]
8. Crystal structure of a soluble form of human CD73 with ecto-5'-nucleotidase activity.
Heuts DP; Weissenborn MJ; Olkhov RV; Shaw AM; Gummadova J; Levy C; Scrutton NS
Chembiochem; 2012 Nov; 13(16):2384-91. PubMed ID: 22997138
[TBL] [Abstract][Full Text] [Related]
9. Potential prognostic biomarker CD73 regulates epidermal growth factor receptor expression in human breast cancer.
Zhi X; Wang Y; Yu J; Yu J; Zhang L; Yin L; Zhou P
IUBMB Life; 2012 Nov; 64(11):911-20. PubMed ID: 23086814
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
Front Immunol; 2022; 13():954039. PubMed ID: 36131912
[TBL] [Abstract][Full Text] [Related]
11. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.
Nakamura Y; Kitano S; Takahashi A; Tsutsumida A; Namikawa K; Tanese K; Abe T; Funakoshi T; Yamamoto N; Amagai M; Yamazaki N
Oncotarget; 2016 Nov; 7(47):77404-77415. PubMed ID: 27764805
[TBL] [Abstract][Full Text] [Related]
13. Highly expressed tumoral emmprin and stromal CD73 predict a poor prognosis for external auditory canal carcinoma.
Miyazaki M; Aoki M; Okado Y; Koga K; Hamasaki M; Nakagawa T; Sakata T; Nabeshima K
Cancer Sci; 2020 Aug; 111(8):3045-3056. PubMed ID: 32473077
[TBL] [Abstract][Full Text] [Related]
14. Blood Predictive Biomarkers for Nivolumab in Advanced Melanoma.
Chasseuil E; Saint-Jean M; Chasseuil H; Peuvrel L; Quéreux G; Nguyen JM; Gaultier A; Varey E; Khammari A; Dréno B
Acta Derm Venereol; 2018 Apr; 98(4):406-410. PubMed ID: 29327065
[TBL] [Abstract][Full Text] [Related]
15. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.
Reinhardt J; Landsberg J; Schmid-Burgk JL; Ramis BB; Bald T; Glodde N; Lopez-Ramos D; Young A; Ngiow SF; Nettersheim D; Schorle H; Quast T; Kolanus W; Schadendorf D; Long GV; Madore J; Scolyer RA; Ribas A; Smyth MJ; Tumeh PC; Tüting T; Hölzel M
Cancer Res; 2017 Sep; 77(17):4697-4709. PubMed ID: 28652246
[TBL] [Abstract][Full Text] [Related]
16. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Gibney GT; Kudchadkar RR; DeConti RC; Thebeau MS; Czupryn MP; Tetteh L; Eysmans C; Richards A; Schell MJ; Fisher KJ; Horak CE; Inzunza HD; Yu B; Martinez AJ; Younos I; Weber JS
Clin Cancer Res; 2015 Feb; 21(4):712-20. PubMed ID: 25524312
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of nivolumab in metastatic melanoma: real-world practice.
Bocquet-Tremoureux S; Scharbarg E; Nguyen JM; Varey E; Quereux G; Saint-Jean M; Peuvrel L; Khammari A; Dreno B
Eur J Dermatol; 2019 Jun; 29(3):315-321. PubMed ID: 31389790
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in previously untreated melanoma without BRAF mutation.
Robert C; Long GV; Brady B; Dutriaux C; Maio M; Mortier L; Hassel JC; Rutkowski P; McNeil C; Kalinka-Warzocha E; Savage KJ; Hernberg MM; Lebbé C; Charles J; Mihalcioiu C; Chiarion-Sileni V; Mauch C; Cognetti F; Arance A; Schmidt H; Schadendorf D; Gogas H; Lundgren-Eriksson L; Horak C; Sharkey B; Waxman IM; Atkinson V; Ascierto PA
N Engl J Med; 2015 Jan; 372(4):320-30. PubMed ID: 25399552
[TBL] [Abstract][Full Text] [Related]
19. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
20. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Topalian SL; Sznol M; McDermott DF; Kluger HM; Carvajal RD; Sharfman WH; Brahmer JR; Lawrence DP; Atkins MB; Powderly JD; Leming PD; Lipson EJ; Puzanov I; Smith DC; Taube JM; Wigginton JM; Kollia GD; Gupta A; Pardoll DM; Sosman JA; Hodi FS
J Clin Oncol; 2014 Apr; 32(10):1020-30. PubMed ID: 24590637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
